pd l1 - Robuta Search

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1269029/full Frontiers | PD-L1 expression complements CALGB prognostic scoring system in malignant pleural... Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelio... pd l1 https://www.preprints.org/manuscript/202506.2221 Glucocorticoids Downregulate PD-L1 Expression in Glioblastoma Cells via GILZ-Dependent Inhibition... Glucocorticoids (GCs), such as dexamethasone (DEX), are commonly administered to glioblastoma (GBM) patients to control cerebral edema; however, their effects... pd l1 https://pdl122c3-learning.dako.com/ The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program pd l1 dako ihc 22c3 pharmdx https://www.pdl1portal.eu/ QuIP PD-L1 Portal pd l1 quip portal https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1224339/full Frontiers | PD-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near... Immune checkpoint blockade is now recognized as a paradigm-shifting cancer therapeutic strategy, whereas there remains difficulty in accurately predicting im... hafnium oxide nanoparticles pd l1 frontiers aptamer functionalized https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1344805/full Frontiers | CD274 (PD-L1) negatively regulates M1 macrophage polarization in ALI/ARDS Background: ALI/ ARDS is a serious clinical syndrome characterized by a high mortality rate. The pathophysiological mechanisms underlying ALI /ARDS remain in... pd l1 https://www.ub.edu/ubtv/video/biomarcadors-pan-tumor-pd-l1-i-altres-biomarcadors Biomarcadors pan-tumor: PD-L1 i altres biomarcadors | UBtv pd l1 pan tumor altres https://www.ub.edu/ubtv/index.php/en/node/122040 Biomarcadors pan-tumor: PD-L1 i altres biomarcadors | UBtv pd l1 pan tumor altres https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-l1-antibody-drug-conjugate-sgn-pdl1v/ Definition of anti-PD-L1 antibody-drug conjugate SGN-PDL1V - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... antibody drug conjugate definition of pd l1 https://www.semanticscholar.org/topic/Anti-PD-L1-Monoclonal-Antibody-LY3300054/9551980 Anti-PD-L1 Monoclonal Antibody LY3300054 | Semantic Scholar A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon... pd l1 monoclonal antibody semantic scholar https://www.news-medical.net/whitepaper/20220208/Host-Directed-Therapeutic-PD-L1-Showing-Potential-to-Cure-Leishmaniasis.aspx Host-directed therapeutic PD-L1 shows potential to cure leishmaniasis Mar 15, 2023 - Host-Directed Therapeutic PD-L1 Shows Potential to Cure Leishmaniasis pd l1 host directed therapeutic shows https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pd-l1 Definition of PD-L1 - NCI Dictionary of Cancer Terms - NCI NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. definition of pd l1 nci dictionary cancer https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2016.00550/full Frontiers | The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation The immune system has the difficult challenge of discerning and defending against a diversity of microbial pathogens, while simultaneously avoiding self-reac... pd l1 https://www.rcsb.org/structure/5X8M RCSB PDB - 5X8M: PD-L1 in complex with durvalumab PD-L1 in complex with durvalumab rcsb pdb l1 complex durvalumab https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic... On March 8, 2019, the Food and Drug Administration granted accelerated approval to atezolizumab (TECENTRIQ, Genentech Inc.) in combination with paclitaxel... pd l1 https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00343/full Frontiers | PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and... The potential of neuroendocrine neoplasms (NEN) to respond to checkpoint inhibitors is largely unknown and full of great expectations. Immunohistochemical (I... pd l1 immune cell frontiers expression https://www.cancer.gov/publications/dictionaries/cancer-drug/def/opucolimab Definition of anti-PD-L1 monoclonal antibody HLX20 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of pd l1 monoclonal antibody https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1275999/full Frontiers | Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2 Accurate structural information plays a crucial role in comprehending biological processes and designing drugs. Indeed, the remarkable precision of the Alpha... pd l1 https://www.goodrx.com/classes/pd-1-pd-l1-inhibitors Popular Pd 1 Pd L1 Inhibitors List, Drug Prices and Medication Information - GoodRx Compare the cost of prescription and generic Pd 1 Pd L1 Inhibitors medications. See information about popular Pd 1 Pd L1 Inhibitors, including the conditions... pd 1 https://www.rcsb.org/structure/5JDR RCSB PDB - 5JDR: Structure of PD-L1 rcsb pdb structure l1 https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1297116/full Frontiers | p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse... Escape from immunosurveillance is a hallmark of chronic lymphocytic leukemia (CLL) cells. In the protective niche of lymphoid organs, leukemic cells suppress... https://www.jci.org/articles/view/91138/figure/1 JCI - PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00819/full Frontiers | Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly... In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy and adjuvant chemotherapy were performed. Brain recurrence and sub... leptomeningeal carcinomatosis https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1209367/full Frontiers | High expression ITGA2 affects the expression of MET, PD-L1, CD4 and CD8 with the immune... Perpose: Pancreatic cancer is characterized by a grim prognosis and is regarded as one of the most formidable malignancies. Among the genes exhibiting high e... https://www.breastcancer.org/research-news/keytruda-plus-chemo-improves-overall-survival-in-strongly-pd-l1-positive-mtnbc Adding Keytruda to Chemotherapy Improves Overall Survival in Metastatic, Strongly PD-L1-Positive... Adding Keytruda to chemotherapy improved overall survival more than chemotherapy alone for metastatic triple-negative, strongly PD-L1-positive breast cancer. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-l1-anti-tgf-beta-bifunctional-fusion-protein-tqb2858 Definition of anti-PD-L1/anti-TGF-beta bifunctional fusion protein TQB2858 - NCI Drug Dictionary -... Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.prnewswire.com/news-releases/new-study-reinforces-clinical-utility-of-combining-tumor-mutation-burden-and-pd-l1-as-predictive-biomarkers-for-immune-checkpoint-inhibitor-therapy-300912065.html New Study Reinforces Clinical Utility of Combining Tumor Mutation Burden and PD-L1 as Predictive... /PRNewswire/ -- Tumor mutational burden (TMB) has recently emerged as a potential biomarker to help guide ICI (immune checkpoint inhibitor) therapy. A new... https://www.mdpi.com/1422-0067/24/22/16386 Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma The introduction of immune checkpoint inhibition for recurrent and metastatic head and neck cancer has brought a new treatment option for patients suffering... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2016.00581/full Frontiers | PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is... The devil facial tumor disease (DFTD) is caused by clonal transmissible cancers that have led to a catastrophic decline in the wild Tasmanian devil (Sarcophi... https://www.mdpi.com/2072-6694/13/17/4409 Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma Immune checkpoint inhibitors (ICI) represent a new therapeutic approach in recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). The patient... https://www.agilent.com/about/newsroom/presrel/2022/15jun-ca22021.html Agilent Receives MFDS Approval in South Korea for Companion Diagnostic PD-L1 IHC 22C3 pharmDx on... https://pmc.ncbi.nlm.nih.gov/articles/PMC5572324/ PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations,... Several cancers are highly refractory to conventional chemotherapy. The survival of tumors in several cases is assisted by checkpoint immunomodulation to... pd 1 https://www.jci.org/articles/view/94196/figure/1 JCI - PD-L1 serves as a double agent in separating GVL from GVHD https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1123244/full Frontiers | The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment... The tumor microenvironment (TME) is the tumor surrounding environment, which is critical for tumor development and progression. TME is also involved in clini... https://www.jci.org/articles/view/94196/pdf JCI - PD-L1 serves as a double agent in separating GVL from GVHD https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.992630/full Frontiers | Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in... Differential responses to immune checkpoint inhibitors (ICI) may be attributed to tumor-intrinsic factors or environmental cues; however, these mechanisms ca... https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1208485/full Frontiers | Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung... The PD-1/PD-L1 axis is hijacked by lung adenocarcinoma (LUAD) cells to escape immune surveillance. PD-L1 expression in LUAD is affected, among others, by the... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1509051/full Frontiers | Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its... BackgroundEsophageal cancer has a poor prognosis despite treatment advancements. Although the benefit of neoadjuvant chemoradiotherapy (CRT) followed by adju... https://pmc.ncbi.nlm.nih.gov/articles/PMC8888121/ Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in... To investigate the regulatory effect of ZEB1 on PD-L1 expression and the pharmacodynamic effects of Biochanin A on the malignant biological behaviors of... https://www.mdpi.com/2072-6694/15/13/3372 Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the... Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential... https://pmc.ncbi.nlm.nih.gov/articles/PMC13064559/ Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1... Telomerase is active in the majority of high-risk neuroblastomas, a pediatric tumor associated with poor patient outcomes. In other cancer types, resistance to... https://www.biospace.com/business/biontechs-ambitious-pd-l1-vegf-plans-currently-rely-on-chinese-manufacturing BioNTech's Ambitious PD-L1/VEGF Plans Currently Rely on Chinese Manufacturing - BioSpace May 5, 2025 - BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a diversified supply chain, executives said... https://www.gene.com/stories/understanding-pd-l1 Genentech: Understanding PD-L1 See why the PD-L1 protein is such an important target in cancer immunotherapy research. genentech understanding pd l1 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1073133/full Frontiers | The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase... Introduction: Immune checkpoint inhibition (ICI) plus bevacizumab (BEV) is the standard first-line treatment for unresectable hepatocellular carcinoma (uHCC)... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10668&r=1 Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck... Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma https://www.nice.org.uk/guidance/ta531 Overview | Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |... Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults https://www.mskcc.org/videos/pd-l1-expression-tnbc-nigeria-dr-gregory-knapp-28-july-2022 July 2022: PD-L1 Expression in TNBC in Nigeria | Memorial Sloan Kettering Cancer Center Presenter: Dr. Gregory Knapp, 28-July-2022 https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.582863/full Frontiers | Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T... Background: The relationship between the interleukin 17 (IL-17) family of cytokines and breast cancer has been widely studied in recent years. Many studies h... https://www.dana-farber.org/clinical-trials/17-727 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma | Dana-Farber... This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.686621/full Frontiers | Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and... Background: Previous studies have explored cancer immunotherapy with radiotherapy or anti-angiogenic therapy, but no trials have reported a triple therapy ap... pd 1 https://pmc.ncbi.nlm.nih.gov/articles/PMC6779807/ Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network... Background: Comprehensive evidence comparing treatment-related adverse events (trAEs) among PD-1/PD-L1 inhibitors is unavailable. Methods: A systematic review... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1534343/full Frontiers | Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic... BackgroundSalivary gland carcinoma (SGC) is an infrequent malignancy characterized by various pathological subtypes. Immune checkpoint inhibitors (ICIs) have... https://www.biospace.com/pathai-composite-pd-l1-and-ai-powered-cd8-topology-biomarker-may-improve-prediction-of-immuno-oncology-treatment-response-in-patients-with-melanoma-at-the-society-for-immunotherapy-of-cancer-meeting-2021 PathAI Composite PD-L1 and AI-powered CD8+ Topology Biomarker May Improve Prediction of... Nov 12, 2021 - PathAI, a global provider of AI-powered technology applied to pathology announced that results from a recent exploratory biomarker analysis on digitized slides... https://www.mayo.edu/research/clinical-trials/cls-20567685 PTT-936, An Alpha Kinase 1 (ALPK1) Activator, Alone Or In Combination With Anti-PD-1/L1 In Patients... Learn more about services at Mayo Clinic. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1392546/full Frontiers | PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy Immunotherapy has been developed, which harnesses and enhances the innate powers of the immune system to fight disease, particularly cancer. PD-1 (programmed... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.955163/full Frontiers | Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer As the predominant treatment option of the immunotherapy for advanced esophageal cancer (EC), the application of programmed death 1 (PD-1) and programmed dea... pd 1 frontiers overcoming resistance https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1486799/full Frontiers | The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory... BackgroundThe introduction of checkpoint immunotherapeutic agents in the last decade has revolutionized cancer treatment. Although anti-PD-1, anti-PD-L1 and ... https://www.jci.org/articles/view/91138/pdf JCI - PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1009254/full Frontiers | Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An... Background: This study aimed to investigate the clinical efficacy of programmed death-1 receptor and ligand-1 (PD-1/PD-L1) inhibitors in gastroesophageal can... https://www.jci.org/articles/view/91138 JCI - PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00604/full Frontiers | The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer The exosome serves as a trafficking vehicle for transport of programmed death-ligand 1 (PD-L1) into receptor cells. In tumor microenvironment, distant tumor ... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-l1-4-1bb-bispecific-antibody-lbl-024 Definition of anti-PD-L1/4-1BB bispecific antibody LBL-024 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.663130/full Frontiers | Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer Thyroid cancer is the most prevalent endocrine malignancy in the US with greater than 53,000 new cases in 2020. There is a significant gender disparity in d... associated with https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.946319/full Frontiers | Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance... The most common subtype of ovarian cancer (OC) is the high-grade serous ovarian carcinoma (HGSOC), accounting for 70-80% of all OC deaths. Although HGSOC is ... https://www.mayo.edu/research/clinical-trials/cls-20318079?&p=1 A Study of MPDL3280A (Anti-PD-L1 Antibody) Combined with Carboplatin and Paclitaxel , and with or... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1468440/full Frontiers | Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with... Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally, particularly when diagnosed at an unresectable stage. Tra... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1521362/full Frontiers | Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial... BackgroundThe combination of programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors with chemotherapy (CT) is currently under evaluation... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.787897/full Frontiers | ARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in... Background: Recent studies have confirmed that AT-rich interactive domain-containing protein 1A (ARID1A) plays a critical role in tumorigenesis, but its role... https://www.deutsche-digitale-bibliothek.de/item/EIHAGCULB6GK7INX7MM3QZAVPHNUNENR Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade... https://www.prnewswire.com/news-releases/rarecyte-announces-the-first-blood-to-result-pd-l1-circulating-tumor-cell-assay-301012173.html RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay /PRNewswire/ -- RareCyte announces a liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on... https://pubhtml5.com/dfsqf/aqux/2022-Anti-CD19_chimeric_antigen_receptor_T_cells_secreting_anti-PD-L1_single-chain_variable_fragment_attenuate_PD-L1_mediated_T_cell_inhibition/ 2022-Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable... Looking for 2022-Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition?... https://www.businesswire.com/news/home/20260326909115/en/Agilent-Receives-FDA-Approval-for-PD-L1-IHC-22C3-pharmDx-in-Esophageal-or-Gastroesophageal-Junction-GEJ-Carcinoma Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction... Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-l1-claudin182-bispecific-antibody-q-1802 Definition of anti-PD-L1/Claudin18.2 bispecific antibody Q-1802 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... https://www.prnewswire.com/news-releases/roche-receives-fda-approval-for-complementary-pd-l1-sp263-biomarker-test-in-urothelial-carcinoma-300449923.html Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinoma /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced approval of the VENTANA PD-L1 (SP263) Assay by the US Food and Drug Administration (FDA) as... https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1004821/full Frontiers | Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in... AbstractBackground: Immune checkpoint inhibitors (ICIs) have been an emerging treatment strategy for advanced triple-negative breast cancer (TNBC). Some stud... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.581189/full Frontiers | Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell... IntroductionThe treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an imm... https://pmc.ncbi.nlm.nih.gov/articles/PMC9760747/ Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1... While anti-PD-1 and anti-PD-L1 [anti-PD-(L)1] monotherapies are effective treatments for many types of cancer, high variability in patient responses is... https://www.marketresearch.com/Bizwit-Research-Consulting-v4223/Global-Immune-Checkpoint-Inhibitors-Size-41117131/ Global Immune Checkpoint Inhibitors Market Size study, by Type (PD-1, PD-L1, CTLA-4), Application... Global Immune Checkpoint Inhibitors Market Size study, by Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast Cancer, Bladder Cancer, Melanoma,... https://pmc.ncbi.nlm.nih.gov/articles/PMC8078320/ Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell... IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed... https://www.mdpi.com/2077-0383/11/6/1627 Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients... Background: Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 improved the survival of non-small cell lung cancer (NSCLC) patients with PD-L1... https://www.marketscreener.com/news/agilent-technologies-inc-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-esophageal-or-gastroe-ce7e51dbda88f427 Agilent Technologies, Inc. Receives FDA Approval For PD-L1 IHC 22C3 PharmDx In Esophageal Or... Mar 26, 2026 - Agilent Technologies Inc. received U.S. Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in... https://www.marketscreener.com/news/boehringer-ingelheim-to-evaluate-combination-of-dll3-targeting-t-cell-engager-plus-pd-l1-vegf-a-bisp-ce7e50dbd08ff027 Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A... Apr 9, 2026 - BioNTech SE: Boehringer Ingelheim: to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.771335/full Frontiers | Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance.Unlike previous surgical, chemotherapy,... pd l1 inhibitor